Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.47 |
| ▸ | CDC25B | P30305 | 8/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.46 |
| ▸ | FGF1 | P05230 | 2/20 | 0.44 |
| ▸ | FGF2 | P09038 | 2/20 | 0.44 |
| ▸ | VEGFA | P15692 | 2/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
| ▸ | GJB2 | P29033 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920538 | 0.97 | NT5E (0.51) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL975079 | 0.90 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL12920536 | 0.90 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL975078 | 0.90 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL12920539 | 0.88 | NT5E (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL12920540 | 0.87 | NT5E (0.50) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL976473 | 0.86 | NT5E (0.51) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL976471 | 0.86 | NT5E (0.51) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL3700974 | 0.85 | ANTXR2 (0.50) | NT5EPTPN1PTPN2PTPN11FGF1 | |
| SCHEMBL9356955 | 0.84 | NT5E (0.53) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875592-B2 | inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-01-25 | — | — | US | disclosed |
| US-20070185037-A1 | Sulfated oligosaccharide derivatives | PROGEN INDUSTRIES LIMITED (AU) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185037-A1 | Sulfated oligosaccharide derivatives | HPSE, APOB, LIPG | NT5E 1735/4885PTPN1 612/4885CDC25B 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.